CIBC Private Wealth Group, LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 39 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2018. The put-call ratio across all filers is 0.60 and the average weighting 0.0%.

Quarter-by-quarter ownership
CIBC Private Wealth Group, LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q1 2020$81,000
+8.0%
17,4840.0%0.00%
Q4 2019$75,000
+10.3%
17,4840.0%0.00%
Q3 2019$68,000
-1.4%
17,4840.0%0.00%
Q2 2019$69,000
-76.5%
17,484
-74.1%
0.00%
-100.0%
Q1 2019$293,000
+452.8%
67,484
+349.9%
0.00%
Q4 2018$53,000
-7.0%
15,0000.0%0.00%
Q3 2018$57,000
-3.4%
15,0000.0%0.00%
Q2 2018$59,000
-71.4%
15,000
-70.0%
0.00%
-100.0%
Q3 2017$206,00050,0000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q3 2018
NameSharesValueWeighting ↓
EAM Investors, LLC 129,929$603,0000.19%
ABNER HERRMAN & BROCK LLC 56,050$260,0000.06%
CFO4Life Group, LLC 12,000$56,0000.03%
Spark Investment Management LLC 12,000$55,0000.03%
Phoenix Holdings Ltd. 118,533$534,0000.03%
HighPoint Advisor Group LLC 13,533$82,0000.02%
GSA CAPITAL PARTNERS LLP 12,500$58,0000.02%
ETF MANAGERS GROUP, LLC 66,197$299,0000.01%
WINTON GROUP Ltd 76,967$357,0000.01%
IHT Wealth Management, LLC 13,000$60,0000.01%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders